Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2/3 1

Status

Terminated 4Completed 4Recruiting 3Active not recruiting 3Withdrawn 1Not yet recruiting 1Available 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Urinary Bladder Neoplasms 6Colorectal Neoplasms 4Carcinoma, Transitional Cell 4Non-Muscle Invasive Bladder Neoplasms 3Neoplasm Metastasis 3Colonic Neoplasms 3Anus Neoplasms 3Sarcoma 2Rectal Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Carcinoma in Situ 2Virus Diseases 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urinary Bladder Diseases 1Neoplasms by Site 1Neoplasm Recurrence, Local 1Nasopharyngeal Carcinoma 1Mycobacterium Infections 1Head and Neck Neoplasms 1Epstein-Barr Virus Infections 1Disease 1Dermatitis 1Carcinoma, Hepatocellular 1Adenoviridae Infections 1

Interventions

pembrolizumab 20atezolizumab 9Nivolumab 9Gemcitabine 9Docetaxel 5avelumab 4Mitomycin 4Carboplatin 4fludarabine 3epacadostat 3enfortumab vedotin 3Cyclophosphamide 3vofatamab 2valrubicin 2rucaparib 2pemigatinib 2durvalumab 2cabozantinib 2Standard of Care 2Sirolimus 2Radiation 2Pemetrexed 2Cisplatin 2Bevacizumab 2B701 protein, Human herpesvirus 6 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2trilaciclib 1temsirolimus 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Transitional Cell × Mitomycin × Clear all
NCT04688931 2024-06-06

ATLAS

UroGen Pharma Ltd.

Phase 3 Terminated
282 enrolled 29 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01438112 2021-04-14

BOND

CG Oncology, Inc.

Phase 2/3 Terminated
22 enrolled
Genitourinary

Adenoviridae Infections, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Virus Diseases

NCT02982395 2019-08-30

Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC

Samyang Biopharmaceuticals Corporation

Phase 3 Terminated
36 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01200992 2017-08-24

EMBARC-RF

Bioniche Life Sciences Inc.

Phase 3 Terminated
84 enrolled 7 charts
Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Mycobacterium Infections, Neoplasm Recurrence, Local, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡